KRAS and colorectal cancer: The inhibition of PBK/TOPK could benefit those colorectal cancer patients with a KRAS or BRAF mutation and those with metastasis, which represented 30–40% of all cases, and this may represent a new avenue of investigation for targeted therapy [54].